Renaissance Technologies’s First Trust NYSE Arca Biotechnology Index Fund FBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-4,300
Closed -$661K 3632
2024
Q1
$661K Sell
4,300
-100
-2% -$15.2K ﹤0.01% 2740
2023
Q4
$695K Sell
4,400
-1,600
-27% -$230K ﹤0.01% 2603
2023
Q3
$878K Buy
6,000
+3,000
+100% +$457K ﹤0.01% 2391
2023
Q2
$459K Buy
+3,000
New +$468K ﹤0.01% 2916
2021
Q2
Sell
-3,100
Closed -$498K 3552
2021
Q1
$498K Buy
+3,100
New +$531K ﹤0.01% 2905
2020
Q3
Sell
-2,300
Closed -$386K 3454
2020
Q2
$386K Buy
+2,300
New +$361K ﹤0.01% 2951
2019
Q3
Sell
-1,500
Closed -$211K 3499
2019
Q2
$211K Buy
+1,500
New +$207K ﹤0.01% 3288
2019
Q1
Sell
-9,700
Closed -$1.21M 3515
2018
Q4
$1.21M Buy
+9,700
New +$1.33M ﹤0.01% 2484
2018
Q2
Sell
-3,700
Closed -$492K 3345
2018
Q1
$492K Buy
+3,700
New +$505K ﹤0.01% 2919

Other funds holding FBT

Renaissance Technologies's FBT Position: Q2 2024 in Review

Renaissance Technologies sold out of First Trust NYSE Arca Biotechnology Index Fund (FBT) in Q2 2024, closing a stake of 4,300 shares — an estimated $661K sold.

Renaissance Technologies first reported a position in FBT in Q1 2018 and held it in 9 quarters. The position peaked at $1.21M in Q4 2018. 251 funds tracked by Wall St. Rank hold FBT as of Q2 2024.

  • Renaissance Technologies reported no remaining First Trust NYSE Arca Biotechnology Index Fund position as of Q2 2024 after selling out during the quarter.
  • Renaissance Technologies sold 4,300 First Trust NYSE Arca Biotechnology Index Fund shares in Q2 2024, an estimated $661K.
  • Renaissance Technologies first reported a position in First Trust NYSE Arca Biotechnology Index Fund in Q1 2018 and held it in 9 quarters.
  • Renaissance Technologies's First Trust NYSE Arca Biotechnology Index Fund position peaked at $1.21M in Q4 2018.
  • 251 funds tracked by Wall St. Rank held First Trust NYSE Arca Biotechnology Index Fund as of Q2 2024.

Based on Renaissance Technologies's 13F filing for Q2 2024, filed 9 Aug 2024.